Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator- controlled clinical trial

Clinical Therapeutics

Volumn 21, Issue 10, 1999, Pages 1653-1663

  Malmstrom, Kerstin ^a,c   Daniels, Stephen ^b   Kotey, Paul ^a   Seidenberg, Beth C ^a   Desjardins, Paul J ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Premier Research   (United States)

^c Maildrop RY32 621 ^*  (United States)

Author keywords

Analgesic; Celecoxib; Cyclooxygenase 2 inhibitor; Ibuprofen; Postoperative dental pain; Rofecoxib

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; HYDROCODONE BITARTRATE; IBUPROFEN; PARACETAMOL; ROFECOXIB; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN ASSESSMENT; POSTOPERATIVE PAIN; RANDOMIZED CONTROLLED TRIAL; TOOTH PAIN; VOMITING;

EID: 0003900038     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80045-9     Document Type: Article

References (24)

1. 1. Smith TJ. Cyclooxygenases as the principal targets for the action of NSAIDs, Rheum Dis Clin North Am. 1998;24:501-523.
2. 2. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993;268:6610-6614.
3. 4, and (s)-flurbiprofen following extraction of impacted third molars. Pain. 1997;73:339-345.
4. 4. Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor. 1994;4:17-23.
5. 5. DeWitt D. Prostaglandin endoperoxide synthase: Regulation of enzyme expression. Biochim Biophys Acta. 1991;1083:121-134.
6. 6. Ehrich EW, Dallob A, de Lepeleire I, et al. Inhibition of the cyclooxygenase-2 isoform by rofecoxib is sufficient for full analgesic efficacy in the dental pain model. Clin Pharmacol Ther. 1999;65:336-347.
7. 7. Ehrich E, Schnitzer T, Kivitz A, et al. MK-966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study. Arthritis Rheum. 1997;40(Suppl 9):S85. Abstract.
8. 8. Cannon G, Caldwell J, Holt P, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial. Arthritis Rheum. 1998;41(Suppl 9):S 196. Abstract.
9. 9. Saag K, Fisher C, McKay J, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial. Arthritis Rheum. 1998;41(Suppl 9):S 196. Abstract.
10. 10. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1591-1602.
11. 11. Hubbard RC, Jasper DR, Nugent MJ, et al. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model. J Invest Med. 1996;44:293A. Abstract.
12. 12. Chan C-C, Boyce S, Brideau C, et al. Rofecoxib (Vioxx®, MK-0966, 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone): A potent and orally active cyclooxygenase-2 inhibitor - pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999; 290:551-560.
13. 13. Mehlisch DR, Mills S, Sandler M, et al. Ex vivo assay of COX-2 inhibition predicts analgesic efficacy in post-surgical pain with MK-0966. Clin Pharmacol Ther. 1998;63:139. Abstract.
14. 14. Brown J, Morrison B, Bitner M, et al. The COX-2 specific inhibitor, MK-0966, is effective in the treatment of primary dysmenorrhea. Clin Pharmacol Ther. 1999;65:118. Abstract.
15. 15. CELEBREX™ Freedom of Information. Washington, DC: US Department of Health and Human Services, Food and Drug Administration; 1999:6-113.
16. 16. Cooper SA. Five studies on ibuprofen for postsurgical dental pain. Am J Med. 1984;77:70-77.
17. 17. FDA Analgesia Guidelines. Washington, DC: US Department of Health and Human Services, Food and Drug Administration; 1997.
18. 18. Vioxx® product information. West Point, Pa: Merck & Co., Inc; 1999.
19. 19. Ibuprofen product information. Florham Park, NJ: Schein Pharma Inc.; 1997.
20. 20. Celebrex™ product information. Chicago/ New York: Searle/Pfizer, 1999.
21. 21. Mehlisch DR, Fulmer RI. A crossover comparison of bromfenac sodium, naproxen sodium, and placebo for relief of pain from primary dysmenorrhea. J Women's Health, 1997;6:83-92.
22. 22. Desjardins PJ, Black PM, Balm TK, et al. Onset of analgesia: Further validation of a new stopwatch method. Clin Pharmacol Ther. 1996;59:130. Abstract.
23. 23. Freund RJ, Littell RC. SAS for Linear Models. Cary, NC: SAS Institute; 1981: 143-151.
24. 24. Laska EM, Sunshine A, Marrero I, et al. The correlation between blood levels of ibuprofen and clinical analgesic response. Clin Pharmacol Ther. 1986;40:1-7.